• Important Safety Information
  • Prescribing Information
  • Medication Guide
  • Clinical References
  • References Request
Logo Logo Logo Logo Logo
  • Why Vibativ
    • Potency
    • Dual MOA
    • Dosing
    • Safety Info
  • HABP/VABP
    • Treating HABP/VABP
    • Subgroups
    • Lung Penetration
    • Concurrent Bacteremia
  • cSSSI
    • TREATING cSSSI
    • Subgroups
    • Tissue Penetration
    • Concurrent Bacteremia
  • Real World Results
    • Outcomes
    • Setting Of Care
    • Pathogens
    • Order of Therapy
    • Adverse Effects
  • Access
    • Order
    • Storage and Handling
    • Billing
    • MIC Test Strips
  • Patient Identifier
  • Why Vibativ
    • Potency
    • Dual MOA
    • Dosing
    • Safety Info
  • HABP/VABP
    • Treating HABP/VABP
    • Subgroups
    • Lung Penetration
    • Concurrent Bacteremia
  • cSSSI
    • TREATING cSSSI
    • Subgroups
    • Tissue Penetration
    • Concurrent Bacteremia
  • Real World Results
    • Outcomes
    • Setting Of Care
    • Pathogens
    • Order of Therapy
    • Adverse Effects
  • Access
    • Order
    • Storage and Handling
    • Billing
    • MIC Test Strips
  • Patient Identifier
Posted at 04 Oct, 12:44h in Business by cdg615 0 Comments
3 Likes
Share

A Look Inside the Protein Bar

Posted at 04 Oct, 12:00h in Sport by cdg615 0 Comments
13 Likes
Share

Unlocking Hidden Brain Secrets

PLEASE SEE FULL PRESCRIBING INFORMATION INCLUDING BOXED WARNING


VIBATIV® (telavancin) Indications
VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria:


Complicated Skin and Skin Structure Infections (cSSSIs)
VIBATIV is indicated for the treatment of adult patients with cSSSIs caused by susceptible isolates of the following Gram-positive microorganisms:

  • Staphylococcus aureus (including methicillin-susceptible and resistant isolates)
  • Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), or
  • Enterococcus faecalis (vancomycin-susceptible isolates only)

    • Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
    VIBATIV is indicated for the treatment of adult patients with HABP/VABP, caused by susceptible isolates of Staphylococcus aureus (including methicillin-susceptible and -resistant isolates).


    VIBATIV should be reserved for use when alternative treatments are not suitable.


    To reduce the development of drug-resistant bacteria and maintain the effectiveness of VIBATIV and other antibacterial drugs, VIBATIV should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.


    IMPORTANT DOSAGE AND ADMINISTRATION INSTRUCTIONS
    Because telavancin is eliminated primarily by the kidney, a dosage adjustment is required for patients whose creatinine clearance is ≤50 mL/min. There is insufficient information to make specific dosage adjustment recommendations for patients with end-stage renal disease (CrCl <10 mL/min), including patients undergoing hemodialysis.


    CONTRAINDICATIONS

  • Intravenous Unfractionated Heparin Sodium
  • Known hypersensitivity to VIBATIV

    • WARNINGS AND PRECAUTIONS

  • Decreased efficacy among patients treated for cSSSI with moderate/severe pre-existing renal impairment. Consider when selecting antibacterial therapy for patients with baseline CrCl ≤50 mL/min.
  • Laboratory tests: interferes with some laboratory coagulation tests, including prothrombin time, international normalized ratio, and activated partial thromboplastin time.
  • Serious and potentially fatal hypersensitivity reactions, including anaphylactic reactions, may occur after first or subsequent doses. Use with caution in patients with known hypersensitivity to vancomycin.
  • Administer VIBATIV over at least 60 minutes to minimize infusion-related reactions.
  • Clostridium difficile-Associated Diarrhea: may range from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.
  • Avoid use in patients at risk for QTc prolongation and who are taking drugs known to prolong the QT interval.

    • ADVERSE REACTIONS
    The most common adverse reaction (≥10% of patients treated with VIBATIV) in the HABP/VABP trials is diarrhea; in the cSSSI trials, the most common adverse reactions (≥10% of patients treated with VIBATIV) include: taste disturbance, nausea, vomiting, and foamy urine.


    IMPORTANT SAFETY INFORMATION


    WARNING: INCREASED MORTALITY IN HABP/VABP PATIENTS WITH PRE-EXISTING MODERATE OR SEVERE RENAL IMPAIRMENT, NEPHROTOXICITY, POTENTIAL ADVERSE DEVELOPMENTAL OUTCOMES


  • Patients with pre-existing moderate/severe renal impairment (CrCl ≤ 50 mL/min) who were treated with VIBATIV for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP) had increased mortality observed versus vancomycin. Use of VIBATIV in patients with pre-existing moderate/severe renal impairment (CrCl ≤ 50 mL/min) should be considered only when the anticipated benefit to the patient outweighs the potential risk.

  • Nephrotoxicity: New onset or worsening renal impairment has occurred. Monitor renal function in all patients.
  • Embryo-fetal toxicity: VIBATIV may cause fetal harm. In animal reproduction studies, adverse developmental outcomes were observed in 3 animal species at clinically relevant doses. Verify pregnancy status in females of reproductive potential prior to initiating VIBATIV. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with VIBATIV and for 2 days after the final dose.
    • Prescribing InformationMedication GuideContact UsPrivacy PolicyTerms of Use
    Cumberland Pharmaceuticals

    VIBATIV® is a registered trademark of Cumberland Pharmaceuticals Inc.

    © Cumberland Pharmaceuticals Inc. Nashville, TN | WWW1300121 | March 2022

    © Vibativ. All Rights Reserved.